Discover Community Create You

Loading publication...

Noodle always counts identifier-free feature events for service operation. With your permission, Google Analytics can also estimate audience and engagement. Search text, publication identifiers, cookies, IP addresses and browser fingerprints are never included in Noodle's first-party event counters.

Privacy details

Article

Mi-2β promotes immune evasion in melanoma by activating EZH2 methylation

9 Mar 2024

Abstract excerpt

Recent development of new immune checkpoint inhibitors has been particularly successfully in cancer treatment, but still the majority patients fail to benefit. Converting resistant tumors to immunotherapy sensitive will provide a significant improvement in patient outcome. Here we identify Mi-2β as a key melanoma-intrinsic effector regulating the adaptive anti-tumor immune response. Studies in genetically...

Read the complete abstract on PubMed

Topics

Share this publication in a Topic to start or enrich a Post.

Share to Cancer Immunotherapy and Biomarkers
Share to Immune cells in cancer
Share to Immunotherapy and Immune Responses

Methodology Data sources Editorial policy Privacy About Contact Helena Bioinformatics

Source

Identifiers

PMID: 38461299
DOI: 10.1038/s41467-024-46422-5

Provenance

PubMed metadata and Literature Corpus relationships. Corpus snapshot updated 8 Sept 2026.

Related research

Semantic proximity does not establish scientific evidence.

Research trail→

Click a neighbor to travelStep 1 · 12 closest

Mi-2β promotes immune evasion in melanoma by activating EZH2 methylationPMID 38461299Read ↗

Mi-2β-targeted inhibition induces immunotherapy response in melanomaSemantic proximity Read ↗

EZH2 Cooperates with DNA Methylation to Downregulate Key Tumor Suppressors and IFN Gene Signatures in Melanoma.Semantic proximity Read ↗

The Histone Methyltransferase Ezh2 Controls Mechanisms of Adaptive Resistance to Tumor ImmunotherapySemantic proximity Read ↗

Targeting DNA Methylation and EZH2 Activity to Overcome Melanoma Resistance to ImmunotherapySemantic proximity Read ↗

MYC Induces Immunotherapy and IFNγ Resistance Through Downregulation of JAK2Semantic proximity Read ↗

<i>ZNF180</i> modulates tumor intrinsic immunotherapy resistance in melanoma through driving plasticitySemantic proximity Read ↗

Stat3 co-operates with mutant <i>Ezh2</i> <sup>Y641F</sup> to regulate gene expression and limit the anti-tumor immune response in melanomaSemantic proximity Read ↗

An actionable axis linking NFATc2 to EZH2 controls the EMT-like program of melanoma cellsSemantic proximity Read ↗

The epigenetic modifier EZH2 controls melanoma growth and metastasis through silencing of distinct tumour suppressors.Semantic proximity Read ↗

PRMT1 acts as a suppressor of MHC-I and anti-tumor immunitySemantic proximity Read ↗

Enhancer Reprogramming in Melanoma Immune Checkpoint Therapy ResistanceSemantic proximity Read ↗

Polycomb repressor complex 2 suppresses interferon-responsive MHC-II expression in melanoma cells and is associated with anti-PD-1 resistanceSemantic proximity Read ↗

⌁Select a neighboring publication to make it the new centre.